Share Name Share Symbol Market Type Share ISIN Share Description
Omega Dia LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.75p -4.62% 15.50p 136,517 12:31:05
Bid Price Offer Price High Price Low Price Open Price
15.00p 16.00p 16.25p 15.50p 16.25p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 14.2 0.7 1.1 14.1 19.68

Omega Diagnostics (ODX) Latest News

More Omega Diagnostics News
Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Share Charts

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date Time Title Posts
16/3/201811:17Omega Diagnostics - nicely poised for significant growth554
01/8/201707:17Omega Diagnostics1,774

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

Omega Diagnostics Daily Update: Omega Dia is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ODX. The last closing price for Omega Diagnostics was 16.25p.
Omega Dia has a 4 week average price of 15.25p and a 12 week average price of 15.25p.
The 1 year high share price is 28.25p while the 1 year low share price is currently 15.25p.
There are currently 126,959,060 shares in issue and the average daily traded volume is 100,470 shares. The market capitalisation of Omega Dia is £19,678,654.30.
barrywhit: You are right p1nkfish IDH performance is dire their share price is dropping even though the only ones buying their shares are them on their share buyback scheme. If the IDH deal doesn't go through I hope ODX can find another partner quickly... I hope every one is safe after the bad weather, I am moving house on Tuesday weather permitting.......
hyperboreus: I am not going anywhere here having initially bought in in March 2012 but as I have stated before there is unlikely to be much positive newsflow short term therefore sliding share price is perfectly understandable but beyond that there should be plenty to look forward to. I personally don't think it is a good idea to obsess about the share price too much at the moment, some investors are clearly losing patience which any reasonable individual should be able to comprehend given the questionable financial performance of the Company in the last few years, but hopefully everything will come together in the next 12-18 months, if not I think something will have to give and the Company may well be bought out, the patience of Sneller and other major investors cannot be inexhaustible.
gwr7: "Mr Shepherd in 2006 led the company through its successful flotation and has been instrumental in growing the group since its first acquisition of Genesis Diagnostics and Cambridge Nutritional Sciences in August 2007." It's a kind report for Mr. Shepherd but as for growing the group since those acquisitions in August 2017 the share price is half what it was back then though I appreciate that doesn't take into account shares issued. It was time for somebody else to have a go. I'm glad he's still involved as he seems very committed to CD4 and I'm sure he can promote it with enthusiasm.
p1nkfish: I think the changes are necessary. Operations CEO is positive move, no good as evangelist. Start-up CEO evangelist spreading the world globally, spot on. Hard to do that and run the show - virtually impossible. Great inconvenience but that is all it is. Results were already determined before CEO change. Onwards for LTHS and others can go their merry way. A big shame about the share price cagr for me but not an existential threat and still believe in the prospects and need for the products/capabilities.
barrywhit: He will have to work hard to get the share price over 50p....he has been at the company since April 2015...
longshanks: Indeed 'tis often so.That said - he does have an active options package requiring the share price to reach 50p before vesting, so any new package will presumably have very similar criteria.
rivaldo: Good news today. Indeed longshanks. It's unusual these days to find highly profitable and well funded small m/cap companies like ODX on a P/E of 18, falling to just 10 next year based on 2.1p EPS forecast from Finncap. Especially with both the near-term blue sky opportunities CD4 and Allersys effectively in the share price for free (or not very much). Plus the chance of other blue sky opportunities like malaria testing etc.
rivaldo: Good to see the share price on a small uptrend post-fundraising. Finncap's latest forecasts are for 1.1p EPS this year, rising to 2.1p EPS next year as some of the blue sky opportunities begin to commercialise. They currently have a 30p target. At that rate of growth it's possible to see a 40p-50p share price in 9 months to a year's time assuming successful achievement of those forecasts - or an outlook which confirms as such.
hyperboreus: Looking like you might get your wish longshanks re 16.5p Been having a really in depth look at all the director share options and the first tranche issued to Evans, Shepherd and Harbinson with exercise price at 19p expire on 10 December 2018 having been issued on 10 December 2008. I am sure they would have been expecting ODX's share price to be much higher by now over 9 years later as it has gone nowhere really since then. The next sizeable batch issued to Shepherd, Harbinson and Grewal with exercise price at 14.5p expire on 5 July 2022 but share price must be 25p or higher. Interestingly David Evans doesn't have any other options other than the one which expires next December, but having said that he was very generously 'allowed' to purchase 2,760,134 shares at 12p on 17 Dec 2010 in a private placing in relation to the purchase of the ALLERGOPHARMA IVD BUSINESS. His average share price purchase by the way is 12.81p, Jag Grewal's is 19.92p, not so easy to work out Harbinson's and Shepherd's as they they were directors in ODX before reverse takeover in 2006 but my best guess for Harbinson is 12.88p and 9.38p for Shepherd. My average share price in ODX has gone up significantly from my first purchase in April 2012 at 10.25p but at just over 16p I am still confident that exciting times are ahead, just not sure how long I might have to wait like the rest of us!
gary38: Omega Diagnostics Group PLC Holding(s) in CompanyIntraday Omega Diagnostics ChartIntraday Omega Diagnostics Chart09/06/2016 8:07amUK Regulatory (RNS & others)TIDMODXRNS Number : 7240AOmega Diagnostics Group PLC09 June 2016TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) --------------------------------------------------------------------------------------------- 1. Identity of the issuer or Omega Diagnostics Group the underlying issuer plc of existing shares to which voting rights are attached: (ii) --------------------------------------------------------------- ---------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): --------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights X ------------------------------------------------------------------- ------------------------ An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------- ------------------------ An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------- ------------------------ An event changing the breakdown of voting rights ------------------------------------------------------------------- ------------------------ Other (please specify): --------------------------------------------------------- -------- ------------------------ 3. Full name of person(s) Richard Edgar Sneller subject to the notification obligation: (iii) ----------------------------------------------------------- -------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ----------------------------------------------------------- -------------------------------- 5. Date of the transaction 8(th) June 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- -------------------------------- 6. Date on which issuer 8(th) June 2016 notified: ----------------------------------------------------------- -------------------------------- 7. Threshold(s) that is/are >6% crossed or reached: (vi, vii) ----------------------------------------------------------- -------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix)---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ------------- --------------- --------------- -------------- -------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- -------------- ------------ ------------ ------------ ----------- GB00B1VCP282 6,515,000 6,515,000 6,765,000 6,765,000 6.22% ------------- --------------- --------------- -------------- ------------ ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------- ---------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) --------------- ------------- ------------- ---------------- ---------------------------- ----------------------- Nominal Delta --------------- ------------- ------------- ---------------- ---------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 6,765,000 6.22% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ------------------------------------------------------------------------------- Proxy Voting: ------------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------------- ---------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- ---------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- ---------------- 13. Additional information: ------------------------------------------------------------- ---------------- 14. Contact name: Richard Sneller ------------------------------------------------------------- ---------------- 15. Contact telephone number: 0131 275 2198 ------------------------------------------------------------- ---------------- This information is provided by RNSThe company news service from the London Stock ExchangeENDHOLUKRWRNSANRRR(END) Dow Jones NewswiresJune 09, 2016 04:07 ET (08:07 GMT)Omega Diagnostics Share Price TodayOmega Diagnostics Share Price ChartOmega Diagnostics Share ChatOmega Diagnostics NewsOmega Diagnostics Share Price HistoryOmega Diagnostics DividendOmega Diagnostics TradesOmega Diagnostics Level 2Add Omega Diagnostics to WatchlistAdd Omega Diagnostics to your PortfolioOmega Diagnostics Share Price AlertSwitch to Desktop View By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & ConditionsShare and Investment Glossary Investment Warning Copyright © 1999 - 2016 Cookie and Privacy Policy
Omega Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180319 23:55:32